Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy DOI Creative Commons
Ri‐Yao Yang, Linlin Sun, Ching-Fei Li

et al.

Nature Communications, Journal Year: 2021, Volume and Issue: 12(1)

Published: Feb. 5, 2021

The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted differentiation, recent evidence suggests that their crosstalk regulates exhaustion immunotherapy efficacy; however, the molecular mechanism is unclear. Here we show contributes to persistence of

Language: Английский

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance DOI Open Access
Sreya Bagchi,

Robert Yuan,

Edgar G. Engleman

et al.

Annual Review of Pathology Mechanisms of Disease, Journal Year: 2020, Volume and Issue: 16(1), P. 223 - 249

Published: Nov. 16, 2020

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer immunotherapy. Starting with approval anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) for advanced-stage melanoma 2011, ICIs-which now also include antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1)-quickly gained US Food Drug Administration treatment a wide array types, demonstrating unprecedented extension patient survival. However, despite success ICIs, resistance to these agents restricts number patients able achieve durable responses, immune-related adverse events complicate treatment. Thus, better understanding requirements effective safe antitumor immune response following ICI therapy is needed. Studies both tumoral systemic changes system yielded insight into basis efficacy resistance. Ultimately, by building on insights, researchers should be combine ICIs other agents, or design new immunotherapies, broader more as well greater safety. Here, we review history clinical utility mechanisms therapy, local associated outcome.

Language: Английский

Citations

1604
Defining ‘T cell exhaustion’ DOI
Christian U. Blank, W. Nicholas Haining, Werner Held

et al.

Nature reviews. Immunology, Journal Year: 2019, Volume and Issue: 19(11), P. 665 - 674

Published: Sept. 30, 2019

Language: Английский

Citations

1194
Clonal replacement of tumor-specific T cells following PD-1 blockade DOI
Kathryn E. Yost, Ansuman T. Satpathy, Daniel K. Wells

et al.

Nature Medicine, Journal Year: 2019, Volume and Issue: 25(8), P. 1251 - 1259

Published: July 29, 2019

Language: Английский

Citations

1190
CD8+ T cell states in human cancer: insights from single-cell analysis DOI
Anne M. van der Leun, Daniela S. Thommen, Ton N. Schumacher

et al.

Nature reviews. Cancer, Journal Year: 2020, Volume and Issue: 20(4), P. 218 - 232

Published: Feb. 5, 2020

Language: Английский

Citations

1139
Pan-cancer single-cell landscape of tumor-infiltrating T cells DOI
Liangtao Zheng, Shishang Qin, Wen Si

et al.

Science, Journal Year: 2021, Volume and Issue: 374(6574)

Published: Dec. 16, 2021

T cells play a central role in cancer immunotherapy, but we lack systematic comparison of the heterogeneity and dynamics tumor-infiltrating across types. We built single-cell RNA-sequencing pan-cancer atlas for 316 donors 21 types revealed distinct cell composition patterns. found multiple state-transition paths exhaustion CD8+ preference those among different tumor Certain populations showed specific correlation with patient properties such as mutation burden, shedding light on possible determinants microenvironment. compositions within tumors alone could classify patients into groups clinical trait specificity, providing new insights immunity precision immunotherapy targeting cells.

Language: Английский

Citations

860
Neoadjuvant checkpoint blockade for cancer immunotherapy DOI Open Access
Suzanne L. Topalian, Janis M. Taube, Drew M. Pardoll

et al.

Science, Journal Year: 2020, Volume and Issue: 367(6477)

Published: Jan. 31, 2020

Presurgical immune checkpoint blockade Checkpoint immunotherapy using antibodies that inhibit the programmed cell death 1 (PD-1) or cytotoxic T lymphocyte–associated protein 4 (CTLA-4) pathways has resulted in unprecedented clinical outcomes for certain cancers such as melanoma. Topalian et al. review advances neoadjuvant (presurgical) an important next step enhancing response of early-stage tumors to blockade. They highlight mechanistic rationale and recent trials based on anti–PD-1 ligand (anti–PD-L1) therapy. Pathological assessment criteria may provide early on-treatment biomarkers predict patient are also discussed. Science , this issue p. eaax0182

Language: Английский

Citations

796
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines DOI Open Access
Eryn Blass, Patrick A. Ott

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 18(4), P. 215 - 229

Published: Jan. 20, 2021

Language: Английский

Citations

754
TIM3 comes of age as an inhibitory receptor DOI Open Access
Yochai Wolf, Ana C. Anderson, Vijay K. Kuchroo

et al.

Nature reviews. Immunology, Journal Year: 2019, Volume and Issue: 20(3), P. 173 - 185

Published: Nov. 1, 2019

Language: Английский

Citations

749
Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms DOI Creative Commons
Jean‐Christophe Beltra, Sasikanth Manne, Mohamed S. Abdel-Hakeem

et al.

Immunity, Journal Year: 2020, Volume and Issue: 52(5), P. 825 - 841.e8

Published: May 1, 2020

Language: Английский

Citations

738
CD8+ T cell differentiation and dysfunction in cancer DOI
Mary Philip, Andrea Schietinger

Nature reviews. Immunology, Journal Year: 2021, Volume and Issue: 22(4), P. 209 - 223

Published: July 12, 2021

Language: Английский

Citations

695